4*
Hikma issued an encouraging trading update this morning. The Group is performing well and management continue to expect Group revenue to grow in the range of 6% to 8% and for core operating profit to be in the range of $700 million to $730 million in 2024, in line with previously upgraded guidance. All 3 segments - Injectables, Branded and Generics – are performing well...from WealthOracle
wealthoracle.co.uk/detailed-result-full/HIK/957 |
Good luck for tomorrow all.Decided to buy 5000 shares today in advance of the update. Lets see where this goes |
Not so much relevant to HIK tho as they only sell generics in North America I believe, non to EU market. Unless anyone knows otherwise. |
You can thank me for the rise as I sold out on Monday. Typical. Whilst I see all good things here, the market doesn't. I thought 25 pounds (interim 22 ) would be reasonable bit it struggles recently to hold above 20. I will be back as its still on my watch list. |
At some point they'll look to exit though, and given their shareholding, can only really do so via selling the whole co |
The Jordanian ownership definitely seems to give it a trading discount |
Jordanian run.Nobody trusts them. Unloved |
I am a little perplexed here.. good performing company, significant improvements over last 12 months, expanding product range, increases in production capability and market potential yet the share price is being stubborn about reflecting that rise.Is this an unloved share or an unloved sector or has the market not picked up on the actual sand potentials here?Any views certainly invited. |
Cheers HH... I see ppl call out these trades and most of the time it's admin from the brokers rather than indicating anything coming ... hikma is a slow moving beast, it's slowly going about its business. Growing at low digits in revenue but divi is growing at a larger percentage which is key to long term holders... |
Apols for delay...The large uncrossing... appears little volume for a while and uncrossing trace unusually large.200k share is 4 million quid. In the context over previous closes it seemed awfully high and wondered if it indicated larger seller / buys around that may place up or down pressure.Whilst I think the share price should be higher, mr market currently disagrees despite a good recent update. |
Director disposal of 35,000 shares. Doesn't always mean much as he may need a new house, maybe divorce who knows. But this guy knows more about the financials than anyone at Hikma. He was CFO for the IPO and is now M&A VP ... |
What's your point, it was at the market price. Only reason to get excited would be if it was materially divergent from it...Not knocking, just interested in what you think it's telling you ... |
That's a big uncrossing trade at the end of the day. Over 200k in shares. |
Surely this should be closer to 2500. Expecting profit upgrade tomorrow |
It's looking like top up time again.Not a stellar performer but a solid steady performer and even a quick 10% return is available here. |
I wish it would make its mind up as to if its going up or down! |
Yes, if you believe that they can grow earnings at mid to high single digit percentages, the multiple should be at least mid teens here. Think its one to just be patient on. Nice to see a little bit of life this morning |
Nothing exceptional in the tu - just confirms that it is relatively cheap as Adam notes.
Odd initial negative reaction this morning, quickly reversed and those getting in early now have a quick gain. I would think that it should share in a general recovery of the sector if interest rates moderate. |
Decent trading statement this morning? PE of only c.11x for this year - feels like good risk/reward bet at these levels IMO |
This is the APH that has nearly halved in 6 months.Trading Hikma is proving profitable and still it's performed far better than your ongoing pumping of APH.I hope people research before buying anything that people are pumping on bulletin boards.. |
An XD related move of ~37p should not have resulted in a ~100p drop in the sp!
I wonder whether it helped to trigger some stop-losses? - Ha-ha. |
Money moving to APH [LSE] , excellent profitable healthcare company |
So a beat on all of those, but quite a lot of exceptional which need looking at - $129m of which opioid related. Agree div increase much more than expected. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
